Medication info
Esomeprazole Magnesium Trihydrate 40 mg Tablet

Esomeprazole Magnesium Trihydrate 40 mg Tablet

Prescription medicationTablet
Ingredient · strength
Esomeprazole Magnesium Trihydrate›44.5mg / 1 tablet
Manufacturer / importer
Shinpharm Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
28 tablets (14 tablets/PTP x 2), 30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201403449 · Approved 2014.07.28 · Insurance code 648507230

Summary

Main use
Treatment of acid-related disorders, Helicobacter pylori eradication, NSAID-related gastrointestinal disturbances and ulcers, and prevention of bleeding
Who uses it
Adults · Children
Adult dosage
1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take it for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. · Once symptoms have resolved, subsequent recurrent symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed use is not recommended for controlling recurrent symptoms in patients at high risk of developing gastric and duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 2) Combination therapy with antibiotics for eradication of Helicobacter pylori Administer this medicine 20 mg in combination with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with the use of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Clinical studies exceeding 4 weeks have not been conducted. 4) Patients requiring continued treatment with nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with the use of nonsteroidal anti-inflammatory drugs: 20 mg once daily. The treatment duration is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with the use of nonsteroidal anti-inflammatory drugs: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. Thereafter, the dose should be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses greater than 80 mg per day should be divided and taken twice daily. 6) Maintenance therapy following intravenous treatment to prevent rebleeding from gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous treatment to prevent rebleeding from gastric or duodenal ulcers. 4. Renal impairment: No dose adjustment is necessary. Use with caution because there is limited experience administering this medicine to patients with severe renal impairment. 5. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. Patients with severe hepatic impairment should not exceed a dose of 20 mg of this medicine. 6. Elderly patients: No dose adjustment is necessary.
Children's dosage
2. Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take it for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. · Once symptoms have resolved, subsequent recurrent symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed use is not recommended for controlling recurrent symptoms in patients at high risk of developing gastric and duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 3. Children under 12 years of age: There is no experience with administering this medicine to children under 12 years of age.

Ingredients

Manufacturer
Shinpharm Co., Ltd.

Efficacy & effects

Treatment of acid-related disorders, Helicobacter pylori eradication, NSAID-related gastrointestinal disturbances and ulcers, and prevention of bleeding

  • Gastroesophageal reflux disease
  • erosive reflux esophagitis
  • esophagitis
  • duodenal ulcers
  • peptic ulcers
  • upper gastrointestinal symptoms
  • pain
  • discomfort
  • burning sensation
  • gastric ulcers
  • duodenal ulcers
  • Zollinger-Ellison syndrome
View approved original text

This medication is used for the treatment of gastroesophageal reflux disease and erosive reflux esophagitis, as well as for the long-term maintenance therapy to prevent recurrence in esophagitis patients. It is also effective for treating and preventing recurrence of duodenal ulcers and peptic ulcers caused by Helicobacter pylori infection. It helps in the short-term treatment of gastrointestinal symptoms related to the use of non-steroidal anti-inflammatory drugs and in the treatment and prevention of gastric ulcers caused by them. Additionally, it is used for the treatment of Zollinger-Ellison syndrome and for the prevention and maintenance therapy of rebleeding from gastric ulcers and duodenal ulcers. Overall, it is widely used for alleviating and treating symptoms of various gastrointestinal-related diseases.

Dosage and Administration

Adult dosage

1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take it for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. · Once symptoms have resolved, subsequent recurrent symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed use is not recommended for controlling recurrent symptoms in patients at high risk of developing gastric and duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 2) Combination therapy with antibiotics for eradication of Helicobacter pylori Administer this medicine 20 mg in combination with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with the use of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Clinical studies exceeding 4 weeks have not been conducted. 4) Patients requiring continued treatment with nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with the use of nonsteroidal anti-inflammatory drugs: 20 mg once daily. The treatment duration is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with the use of nonsteroidal anti-inflammatory drugs: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. Thereafter, the dose should be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses greater than 80 mg per day should be divided and taken twice daily. 6) Maintenance therapy following intravenous treatment to prevent rebleeding from gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous treatment to prevent rebleeding from gastric or duodenal ulcers. 4. Renal impairment: No dose adjustment is necessary. Use with caution because there is limited experience administering this medicine to patients with severe renal impairment. 5. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. Patients with severe hepatic impairment should not exceed a dose of 20 mg of this medicine. 6. Elderly patients: No dose adjustment is necessary.

Children's dosage

2. Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take it for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. · Once symptoms have resolved, subsequent recurrent symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed use is not recommended for controlling recurrent symptoms in patients at high risk of developing gastric and duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 3. Children under 12 years of age: There is no experience with administering this medicine to children under 12 years of age.

Precautions

This medication should not be administered to certain patients. For example, patients who are allergic to this medication or its components, or who have experienced hypersensitivity reactions, should not use it. Additionally, patients allergic to penicillin antibiotics or macrolide antibiotics should not use this medication in combination therapy for the eradication of Helicobacter pylori. Patients taking certain cardiac-related medications or with a history of myocardial infarction, as well as nursing women, should not take this medication. Since this medication can cause various adverse reactions, if symptoms such as headache, dizziness, abdominal pain, skin rash, or muscle pain occur during use, consult a doctor immediately. Long-term use requires regular monitoring, such as blood tests or magnesium level checks, and extra caution is needed if taken for more than one year. This medication may increase the risk of bacterial infection in the gastrointestinal tract due to its acid-reducing effect, so patients should report to healthcare professionals if diarrhea persists or symptoms worsen. Additionally, long-term use may increase the risk of fractures, so patients at risk for osteoporosis may need monitoring, such as bone density tests. This medication has a high potential for drug interactions, so dosage adjustments or precautions are needed based on other medications being taken; therefore, all concurrent medications should be reported to healthcare professionals. Pregnant or nursing women should consult with a doctor about the use of this medication, and nursing mothers are advised to avoid taking this medication. In case of overdose, there is no specific antidote, so individuals should go to a medical facility immediately for appropriate treatment and keep it out of reach of children.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, agitation, mental confusion, depression, aggression, hallucinations, headache, dizziness, paresthesia, drowsiness, taste disturbance, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal bloating, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, elevated liver enzymes, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, eosinophilia with systemic symptoms drug reaction, fractures, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal bloating, allergic reactions, back pain, chest pain, substernal chest pain, facial edema, facial flushing, fatigue, fever, influenza-like illness, generalized edema, leg edema, malaise, pain, stiffness, peripheral edema, flushing, hypertension, tachycardia, goiter, irritable bowel syndrome, exacerbation of constipation, dyspepsia, dysphagia, gastrointestinal dysmotility, epigastric pain, belching, esophageal disorders, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, melena, oral disorders, pharyngeal disorders, rectal disorders, gastrointestinal symptoms, elevated serum gastrin, tongue disorders, tongue edema, ulcerative stomatitis, vomiting, ear pain, tinnitus, anemia, hypopigmented anemia, cervical lymphadenopathy, epistaxis, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, abnormal liver function, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, thirst, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, convulsions, fibromyalgia syndrome, hernia, rheumatic polymyalgia, arthralgia, loss of appetite, apathy, increased appetite, confusion, worsening depression, generalized muscle hypertonia, agitation, sensory loss, erectile dysfunction, insomnia, migraine, exacerbation of migraine, sleep disturbances, tremors, dizziness, visual field defects, paresthesia, drowsiness, dysmenorrhea, menstrual disorders, vaginitis, exacerbation of asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, rash, erythmatous rash, papular rash, angioedema, dermatitis, itching, urticaria, increased sweating, otitis media, hyposmia, anosmia, dysuria, albuminuria, cystitis, dysuria, fungal infections, hematuria, frequency of urination, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcers, esophageal varices, gastric ulcers, gastritis, benign polyps or nodules, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. The recommended storage temperature is between 1 to 30 degrees Celsius at room temperature.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

28 tablets (14 tablets/PTP x 2), 30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.